Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEBGet Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 4,600 shares, an increase of 39.4% from the February 29th total of 3,300 shares. Based on an average daily volume of 8,700 shares, the short-interest ratio is presently 0.5 days. Approximately 0.1% of the shares of the company are sold short.

Anebulo Pharmaceuticals Stock Performance

Shares of NASDAQ:ANEB opened at $2.87 on Friday. The company’s fifty day moving average is $2.64 and its two-hundred day moving average is $2.55. Anebulo Pharmaceuticals has a 1-year low of $1.62 and a 1-year high of $4.05. The stock has a market capitalization of $73.56 million, a price-to-earnings ratio of -6.83 and a beta of -1.02.

Anebulo Pharmaceuticals (NASDAQ:ANEBGet Free Report) last announced its quarterly earnings data on Tuesday, February 13th. The company reported ($0.11) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.11). Sell-side analysts expect that Anebulo Pharmaceuticals will post -0.47 EPS for the current fiscal year.

Institutional Trading of Anebulo Pharmaceuticals

A hedge fund recently raised its stake in Anebulo Pharmaceuticals stock. Vanguard Group Inc. increased its stake in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEBFree Report) by 39.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,344 shares of the company’s stock after buying an additional 6,312 shares during the quarter. Vanguard Group Inc. owned about 0.09% of Anebulo Pharmaceuticals worth $68,000 at the end of the most recent quarter. 28.40% of the stock is currently owned by hedge funds and other institutional investors.

Anebulo Pharmaceuticals Company Profile

(Get Free Report)

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.

Further Reading

Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with's FREE daily email newsletter.